Severe vascular calcifications, alterations in cardiovascular structure and function, immune dysfunction, and anemia are adverse effects of parathyroid hormone (PTH), which may contribute to increase risk factors of cardiovascular morbidity and mortality among renal failure patients. To evaluate the potential risk factors for mortality due to cardiovascular disease among hemodialysed patients in Indonesia, this cohort study was conducted. This study included 178 patients on hemodialysis who had been followed up two times a week for nine months (prospective cohort) and 185 patients who died in the last five years (retrospective cohort). Universal sampling technique were used to select the study subjects. Male was prevalence among hemodialysed patients in hemodialysis center, Jakarta, Indonesia and the third group of age (51-60 years) was predominant among these patients. Java ethnicity was found in almost 50% hemodialysed patients in this hemodialysis center. Most of those patients had hypertensive family history. Besides that, more than 70 percent of them were married and non-smoker. The study found that cardiovascular disease caused mortality among hemodialysed patients in Indonesia and the duration of cardiovascular disease influenced the probability of death/risk of mortality among these patients (HR 2.39, p = 0.006). Mortality among patients on hemodialysis in this study was caused by cardiovascular disease, and this cause of death was included in one of the biggest causes. During the study, several practice patterns revealed no PTH level check, no patients got calcimimetic agents such as rocalcitriol/calcitriol and calcium value check was conducted irregularly. As we know, there is a correlation between PTH, calcium and cardiovascular disease. Hence, mortality due to cardiovascular disease among hemodialysed patients significantly correlated with the duration of cardiovascular disease, and potentially with lack of PTH check, calcium check and rocalcitriol/calcitriol supplement given to those patients.


Annual Data Report Minneapolis. (2006). Renal Data System US.

Almeida, F. A. De, Ciambelli, G. S., Bertoco, A. L., Jurado, M. M., Siqueira, G. V., Bernardo, E. A., … Gianini, R. J. (2015). Family Clustering of Secondary Chronic Kidney Disease with Hypertension or Diabetes Mellitus. A Case-Control Study. Ciência & Saúde Coletiva, 20(2), 471–478.

Block, G. A., & Port, F. K. (2000). Re-evaluation of risks associated with hyperphosphatemia and hyperparathyroidism in dialysis patients: recommendations for a change in management. American Journal of Kidney Diseases : The Official Journal of the National Kidney Foundation, 35(6), 1226–1237. https://doi.org/10.1016/S0272-6386(00)70064-3

Flanc, R. S., Roberts, M. A., Strippoli, G. F., Chadban, S. J., Kerr, P. G., & Atkins, R. C. (2004). Treatment of diffuse proliferative lupus nephritis: a meta-analysis of randomized controlled trials. American Journal of Kidney Diseases: The Official Journal of the National Kidney Foundation, 43(2), 197–208. https://doi.org/10.1053/j.ajkd.2003.10.012

Ganesh, S. K., Stack, A. G., Levin, N. W., Hulbert-Shearon, T., & Port, F. K. (2001). Association of elevated serum PO(4), Ca x PO(4) product, and parathyroid hormone with cardiac mortality risk in chronic hemodialysis patients. Journal of the American Society of Nephrology : JASN, 12(10), 2131–2138.

Greten, J., Kreis, I., Wiesel, K., Stier, E., Schmidt, A. M., Stern, D. M., … Nawroth, P. P. (1996). Receptors for advance glycation end-products (AGE) - expression by endothelial cells in non-diabetic uraemic patients. Nephrol Dial Transplant, 11(5), 786–790. Retrieved from http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=8671895

Hallan, S. I., & Orth, S. R. (2011). Smoking is a risk factor in the progression to kidney failure. Kidney International, 80(5), 516–523. https://doi.org/10.1038/ki.2011.157

Hayen, A., Pellegrini, F., Craig, J. C., & Chb, M. B. (2017). Serum Levels of Phosphorus, Parathyroid Hormone, and Calcium and Risks of Death. JAMA, 305(11), 1119–1127.

Herzog, C. A., Asinger, R. W., Berger, A. K., Charytan, D. M., ez, J. D. iacute, Hart, R. G., … Ritz, E. (2011). Cardiovascular disease in chronic kidney disease. A clinical update from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney International, 80(6), 572–586. https://doi.org/10.1038/ki.2011.223

Indonesian Renal Registry. (2014). 7th Report of Indonesian Renal Registry 2014.

Malluche, H. H., Ritz, E., Lange, H. P., Kutschera, J., Hodgson, M., Seiffert, U., … Lange, H. P. (1976). Bone histology in incipient and advanced renal failure. Kidney International, 9(4), 355–362. https://doi.org/10.1038/ki.1976.42

Marry Anne, K.-K., & Alledredge, B. K. (2013). Koda-Kimble and Young’s Applied Therapeutics: The Clinical Use of Drugs.

McDonald, S. P. (2015). Australia and New Zealand Dialysis and Transplant Registry. Kidney International Supplements, 5(1), 39–44. https://doi.org/10.1038/kisup.2015.8

Moe, S. M., Drüeke, T., Lameire, N., & Eknoyan, G. (2007). Chronic Kidney Disease–Mineral-Bone Disorder: A New Paradigm. Advances in Chronic Kidney Disease, 14(1), 3–12. https://doi.org/10.1053/j.ackd.2006.10.005

National Kidney Foundation. (2003). K/DOQI clinical practice guidelines for managing dyslipidemias in chronic kidney disease. Am J Kidney Dis, 41(4, Suppl 3), S1–S91. https://doi.org/S0272638603001197 [pii]

National Kidney Foundation. (2009). KDIGO Clinical Practice Guideline for the Diagnosis , Evaluation , Prevention , and Treatment of Chronic Kidney Disease-Mineral and Bone Disorder ( CKD-MBD ). Kidney International, 76(August).

National Kidney Foundation. (2013). KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney International, 3(1), Supplement. https://doi.org/10.1038/kisup.2012.76

Nikodimopoulou, M., & Liakos, S. (2011). Secondary hyperparathyroidism and target organs in chronic kidney disease. Hippokratia, 15(Suppl 1), 33–38.

Pitts, T. O., Piraino, B. H., Mitro, R., Chen, T. C., Segre, G. V., Greenberg, A., & Puschett, J. B. (1988). Hyperparathyroidism and 1,25-dihydroxyvitamin D deficiency in mild, moderate, and severe renal failure. The Journal of clinical endocrinology and metabolism, 67(5), 876–881. https://doi.org/10.1210/jcem-67-5-876.

Venícios, M., Lopes, D. O., Luisa, A., & Carvalho, B. De. (2017). Excess fluid volume : sociodemographic and clinical analysis in haemodialysis patients. Rev Bras Enferm (REBEn), 70 (1), 11–17.



To view the content in your browser, please download Adobe Reader or, alternately,
you may Download the file to your hard drive.

NOTE: The latest versions of Adobe Reader do not support viewing PDF files within Firefox on Mac OS and if you are using a modern (Intel) Mac, there is no official plugin for viewing PDF files within the browser window.